Kornimate/medical-research-clean huggingface dataset:
shengyu decoction and lijin manipulation for knee oa: 3d gait analysis

Conditions: Osteoarthritis of the Knee

Summary: detailed description avoid duplicating information that will be entered or uploaded elsewhere in the record.

this study aims to explore the efficacy of the shengyu decoction combined with manual therapy for the treatment of knee osteoarthritis (oa) using a clinical randomized controlled trial design. additionally, based on three-dimensional gait analysis technology, the investigators will delve into the biomechanical mechanisms underlying the onset of knee oa and elucidate the mechanism of action of the shengyu decoction combined with manual therapy. this will further validate the clinical superiority of the shengyu decoction combined with manual therapy in the treatment of knee oa, providing strong support for reducing pain and improving knee function in patients with knee oa.

Eligibility criteria:
inclusion criteria: * diagnostic criteria of western medicine: knee pain for at least 1 month, x-ray showing osteophyte formation, age ≥50 years, morning stiffness ≤30 min, and bone fricative sound. * tcm diagnostic criteria: dull pain in the knee joint, flexion and extension limitations, pitching and side rotation unfavorability, slight activities slightly relieve pain, climate change aggravates symptoms, and repeated middle-aged and elderly patients, hidden onset, slow onset, slight local swelling of the knee joint, friction or clicking sound when moving, and severe cases may show muscle atrophy and joint deformity. * radiographs showing joint space narrowing, bone hyperplasia, subchondral osteosclerosis, and osteophyte formation. * patients who are between 45 and 85 years old. * patients who can understand and provide informed consent. * patients who are willing and able to undergo manual treatment for 1 course of treatment and cooperate with the doctor to complete the study. exclusion criteria: * patients who do not meet the diagnostic criteria for knee osteoarthritis established by the rheumatology society. * severe knee pain with surgical indications (or x-ray grading standards reached level 4). * pregnant or planning to become pregnant. * patients who have participated in or are participating in other clinical trials within the last 3 months. * patients who have received or are receiving other treatment methods such as drugs that affect the evaluation of efficacy within the past 3 months. * patients with fractures, dislocation, skin damage, and severe infectious skin diseases within three weeks. * patients with severe primary diseases such as liver, kidney, hematopoietic system, endocrine system, cardiovascular and cerebrovascular, nervous system, tuberculosis, joint malformations, tumors, and psychiatric patients and postoperative patients. * patients who are unable to accurately evaluate the effectiveness and safety of treatment due to their medical condition.
assessment of tobacco smoking and alcohol drinking and treatment outcomes among patients with lung or head and neck cancer

Conditions: Lung or Head and Neck Cancer

Summary: the overarching goal of the proposed study is to provide information which can lead to effective implementation of cessation support in the care of smokers diagnosed with lung or head \& neck cancer. to achieve these aims, the study propose to conduct a longitudinal cohort study of patients diagnosed with lung or head \& neck cancer at the hospices civils de lyon (smallhan). briefly, adult patients newly diagnosed with lung or head \& neck cancer will be recruited at the time of diagnosis (announcement of diagnosis and consultation).


Eligibility criteria:
inclusion criteria: * patients newly diagnosed with lung cancer or head \& neck cancer (international classification of diseases 10: c76, c34) * patients who undergo front-line treatment * age 18 years or older * benefiting from a social security scheme * written information about the study provided to the patient before any procedure specific to the study * patients who had at least one episode of smoking within the past 30 days before diagnosis exclusion criteria: * history of another lung or head \& neck cancer \< 5 years (note: the presence of a second tumour location, discovered at the same time as the lung or head and neck cancer, does not constitute a non-inclusion criterion) * history of another cancer (except for curatively treated cervical cancer in situ and non-melanoma skin cancer) \< 3 years * mesothelioma, thymic malignancies, and cancer of the upper oesophagus * inability to complete the study for psychosocial reasons (inability to schedule interview (homeless), no access to phone, psychological disorder leading to inability to answer phone interview, do not speak french and no easy access to translator from surroundings) * patient under guardianship * patient refusal

Keywords: lung cancer head and neck cancer tabacco alcohol
pms of trazenta on the long-term use as add-on therapy

Conditions: Diabetes Mellitus, Type 2

Summary: study to investigate the safety and efficacy of long-term daily use of trazenta® tablets as add-on therapy in patients with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: patients with type 2 diabetes mellitus who are treated with anti-diabetic drugs and have never been treated with trazenta® tablets (linagliptin) before enrollment will be included. exclusion criteria: none
whipple procedure: a 5-year clinical experience in tertiary care center

Conditions: Whipple Procedure

Summary: the study was conducted in tertiary care hospital of lahore. patient undergoing whipple procedure were studied by compiling demographic details of the patients, common presenting symptoms, various indications for whipple's procedure, the cofactors which affect the procedures outcome and morbidity and mortality of the patients.

this study was performed by collecting data through predesigned questionnaire about patients undergoing whipple's procedure from operation theatres and medical record section. those patients, whose tumor was unresectable and undergone palliative surgical procedures were excluded from the study.

Eligibility criteria:
inclusion criteria: * patients of both sexes with age ranging from 20 years to 70 years * patients with pancreatic tumors * patients with adequate cardiorespiratory reserves to be fit for prolong general anesthesia exclusion criteria: * unresectable tumors * unfit for surgery

Keywords: whipple procedure, pancreatic carcinoma, biliary stenting,
a case-control study to assess the association between facial characteristics and coronary artery diseases

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to explore the facial characteristics associated with the increased risk of coronary artery diseases. the secondary purpose is to evaluate the diagnostic efficacy of appearance factors for coronary artery diseases.

several age-related appearance factors were described associated with increased risk of coronary artery diseases (cad). however, several limitations made these facial risk factors hard to be utilized in clinical practice, including 1) low prevalence in cad patients, 2) lack of specific definition, 3) poor reproducibility in artificial recognition. thus, we designed a case-control study to explore new, common and well-defined facial characteristics associated with cad and evaluate the diagnostic efficacy of appearence factors in cad. we will recuit 1150 patients with at least one coronary lesion stenosis ≥50% according to coronary angiography or coronary computer tomography (cad group) and 1150 patients without coronary lesion stenosis≥ 50% (no cad group) judged by coronary angiography or coronary computer tomography. we will collect patients' baseline information and facial images. one hand, we will explore the facial factors associated with cad by comparing the exposure rates of different facial factors in cad group and no cad group based on artificial intelligence technology. on the other hand, we will build a cad risk model based on facial factors, and evaluate the diagnostic effect of the model.

Eligibility criteria:
inclusion criteria: * undergoing coronary computer tomography or coronary angiography * written informed consent exclusion criteria: * prior percutaneous coronary intervention (pci) * prior coronary artery bypass graft (cabg) * without blood biochemistry outcome * with artificially facial alteration (i.e. cosmetic surgery, facial trauma or make-up) * other situations which make patients fail to be photographed

Keywords: artificial intelligence facial recognition facial characteristic
palbociclib in combination with fulvestrant or letrozole in patients with er+, her2- advanced breast cancer

Conditions: Metastatic Breast Cancer

Summary: this is an international, randomized, open-label, controlled, multicenter phase ii clinical trial to investigate and compare the safety and efficacy of palbociclib combined with fulvestrant or letrozole in women with er+, her2- locally advanced or metastatic breast cancer.

patients will be stratified by site of disease (visceral vs. non-visceral) and by onset of metastatic disease diagnose (patients metastatic de novo versus non de novo).

Eligibility criteria:
inclusion criteria: 1. women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy 2. confirmed diagnosis of hr+/her2- breast cancer 3. post-menopausal status 4. no prior chemotherapy line in the metastatic setting 5. measurable disease defined by recist version 1.1, or non-measurable disease 6. eastern cooperative oncology group (ecog) ps 0-1 7. adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures 8. resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to ncictcae version 4.0 grade equal or minor than 1 exclusion criteria: 1. er or her2 unknown disease 2. her2 positive disease based on local laboratory results 3. locally advanced breast cancer candidate for a radical treatment 4. prior (neo)adjuvant endocrine treatment with dfi ≤ 12-months from completion of treatment. 5. patients with rapidly progressive visceral disease or visceral crisis. 6. major surgery within 4 weeks of start of study drug 7. patients with an active, bleeding diathesis 8. serious concomitant systemic disorder incompatible with the study 9. are unable to swallow tablets 10. chronic daily treatment with corticosteroids with a dose of ≥ 10mg/day methylprednisolone equivalent 11. known active uncontrolled or symptomatic cns metastases 12. known hypersensitivity to letrozole, fulvestrant or any of their excipients, or to any pd-0332991 excipients 13. qtc \> 480 msec on basal assessments, personal history of long or short qt syndrome, brugada syndrome or known history of qtc prolongation, or torsade de pointes 14. uncontrolled electrolyte disorders that can compound the effects of a qtc-prolonging drug

Keywords: metastatic breast cancer endocrine receptors positive her-2 negative
safety and efficacy of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm

Conditions: Atrial Fibrillation or Flutter

Summary: lgn-vn-003 is a prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation (af) or atrial flutter (afl) to normal sinus rhythm. up to 625 subjects will be randomized in a 2:1 fashion so at least 400 vanoxerine and 200 placebo subjects receive study drug.


Eligibility criteria:
inclusion criteria: * subject has been informed of the investigational nature of this study and has given written informed consent in accordance with institutional, local, and national guidelines. * able to return for day 8 follow up. * male or female 18 years of age or greater. * onset of af/afl within the 7 calendar days preceding randomization, based on symptoms. * af/afl documented by ecg during the screening period. * adherence to local clinical standards or the acc/aha or esc practice guidelines for af/afl regarding thromboembolic event prevention and treatment. exclusion criteria: * previous exposure to vanoxerine hcl. * women of childbearing potential (neither surgically sterilized nor post-menopausal defined as cessation of menses for over one year) * systolic blood pressure \<110 mmhg (unless documented to be usual value). * average heart rate \<60 bpm documented by screening ecg. * average qtc \>440 msec documented by screening ecg. * qrs interval \>140 msec documented by screening ecg. * paced atrial rhythm on screening ecg. * history of receiving another class i or class iii antiarrhythmic drug within 3 days prior to randomization. excluded class i antiarrhythmic drugs include quinidine, procainamide, disopyramide, lignocaine, mexilitine, flecainide, and propafenone. excluded class iii drugs include dofetilide, sotalol, dronedarone, and ranolazine. * history of amiodarone (oral or iv) within the 90 days prior to randomization. * native or prosthetic aortic or mitral stenosis with aortic valve area ≤1.0 cm2 or mitral valve area of \<1.5 cm2 or any other valvular diseases for which surgery is indicated. * treatment with any loop diuretic (e.g., furosemide, bumetanide, torsemide, ethacrynic acid, etc.) in the 30 days prior to randomization. * ejection fraction of \<35% within the 3 months prior to randomization (most recent measure if more than one). * af/afl as a result of surgery (postoperative af/afl) within 30 days prior to randomization. * history of electrical cardioversion within the 7 calendar days prior to randomization. * history of any polymorphic ventricular tachycardia including torsades de pointes. * history or family history of long qt syndrome or other inherited arrhythmia syndrome. * history of ventricular tachycardia requiring drug or device therapy.
the glucose transporter type i deficiency (g1d) registry

Conditions: GLUT1 Deficiency Syndrome; Glucose Transporter Type 1 Deficiency Syndrome; Glucose Transporter Type1 (GLUT-1) Deficiency; GLUT-1 Deficiency Syndrome

Summary: the purpose of this protocol is to create a registry for patients diagnosed with glucose transporter type 1 deficiency (g1d), or patients experiencing symptoms consistent with g1d but not yet diagnosed, to enter medical information for physicians and other health researchers to analyze to increase the understanding of g1d and any sub-diagnoses.

this is a registry for patients diagnosed with g1d, or experiencing symptoms g1d but not yet diagnosed. the registry will be available online for patients to provide consent, register, enter data, and modify data as necessary. the registry will be programmed by programmers at ut southwestern medical center. the registry will provide the opportunity for patients to enter a comprehensive medical history, from symptoms to lab results to medications and other treatment regimens. this registry is entirely patient-driven; no medical records will be requested by the investigator, nor are visits with the investigator or any other research personnel required. the registry database will be periodically "cleaned"; that is, records will be reviewed for duplication of entries and consistency of data. many data validation checks are incorporated into the registry. additional data clarification may be requested from users if users have chosen to provide an email address for contact.

Eligibility criteria:
inclusion criteria: * males and females * g1d diagnosis * patients experiencing symptoms of g1d but who have not yet received a diagnosis exclusion criteria: * patients who are not experiencing any symptoms of g1d

Keywords: glucose transporter type i deficiency glucose transporter type 1 deficiency g1d glut1 deficiency
study to evaluate the efficacy of in sti-9199 in treating symptomatic covid-19 in outpatient adults and adolescents

Conditions: COVID-19

Summary: this is a phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal sti-9199 in adults and adolescents who are covid-19 positive with mild to moderate symptoms.

this is a phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal sti-9199 in adults and adolescents who are covid-19 positive with mild to moderate symptoms. this is a single dose study and three different dose concentrations will be compared to placebo.

Eligibility criteria:
inclusion criteria: * otherwise healthy, positive for covid-19 by an eua-approved rapid antigen or pcr test, has ongoing "mild to moderate illness or symptoms" with symptom onset starting \< 5 days prior to screening visits * must provide written informed consent/assent if a minor which includes signing the institutional review board/independent ethics committee approved consent form prior to participating in any study related activity * willing and able to comply with study procedures and follow-up visits * willing to follow all contraception guidelines exclusion criteria: * in the investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe covid-19 illness/symptoms * any medical condition that, in the investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study * has a prior history of long covid * has a clinically documents acute infection other than covid-19 * known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding * has participated, or is participating in a clinical reserach study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or iv immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

Keywords: covid-19
toward self-management in ild

Conditions: Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Connective Tissue Related ILD; Chronic Hypersensitivity Pneumonitis; Fibrotic Lung Disease

Summary: treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. self-management is advocated as a mechanism that can empower service users with long term conditions to choose healthier options and also transform the relationship between service user and caregivers from one in which the former is a passive recipient of care to one in which they are an active partner in decision-making. interstitial lung disease (ild) is one such long term condition. patients with ild often express concern about the lack of information on possible rehabilitation programmes and other services that could potentially improve self-management of the disease. in addition, there is a general perception about a lack of co-ordination between health care professionals especially in relation to referral to services for comprehensive management of the disease. therefore, the needs of patients with ild and their carers, and possible gaps in service provision need to be explored further. in this study, the investigators propose to explore the needs of ild patients from all types of ild and all stages of severity and to also involve carers and clinicians. the investigators will conduct three focus groups for patients and carers and six one-to-one interviews with clinicians to explore perceptions about service gaps and needs in two ild centres in south and north london, uk. this study will provide valuable information to develop the building blocks of a self-management resource and will enable the investigators to make it specific to the different types of ild.


Eligibility criteria:
patients inclusion criteria: * diagnosed with interstitial lung disease (all types apart from sarcoidosis) * age \>18 years * at least one consultation with a health care professional exclusion criteria: * diagnosed with sarcoidosis * unable to communicate in english * severity of condition and commodities preventing participation caregivers inclusion criteria: - currently caring for a participant with ild exclusion criteria: - unable to communicate in english clinicians: inclusion criteria: - involved in the clinical management and treatment of ild patients exclusion criteria: - health care professionals not directly involved in management or treatment of ild patients

Keywords: interstitial lung disease self-management service provision
role of angiogenesis in dermatologic diseases: a potential therapeutic target

Conditions: Dermatologic Diseases

Summary: the researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease. biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. some specimens may also undergo genetic analysis to investigate underlying molecular pathways. de-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.

biospecimens from various dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis will be evaluated for markers of angiogenesis. additionally, researchers can use discarded human skin tissue samples from skin biopsy/surgery sites, which are removed for closure but are not submitted for histopathologic analysis. we may use donated tissue with both dermatologic disease and non-diseased tissue from the same donor. biopsies may also be taken for molecular and genetic analysis of specimen. non-identifiable information regarding the patient, such as age, sex, race, cause of death, location, and description of diseased skin may be recorded.

Eligibility criteria:
inclusion criteria: * 16 years of age or older. * willing to have a skin biopsy exclusion criteria: * under 16 years of age * unable to carry out instructions

Keywords: dermatologic diseases